TL;DR
- •Rebound anxiety is the paradoxical increase in anxiety produced by benzodiazepines — between doses (interdose withdrawal), during tolerance development, or during withdrawal.
- •The mechanism: chronic benzodiazepine exposure downregulates GABA receptors, so the brain experiences increased anxiety when benzodiazepine levels fall. The medication that initially treated anxiety eventually drives it.
- •Worst with short-half-life agents: alprazolam (Xanax) and lorazepam (Ativan) produce the most pronounced interdose rebound. Long-half-life agents (clonazepam, diazepam) produce less interdose effect but still drive tolerance and withdrawal over time.
- •Patients often interpret rebound anxiety as their underlying anxiety worsening — leading to dose increases that perpetuate the cycle. Recognizing it as iatrogenic is the first step in breaking the loop.
- •Management requires gradual tapering with clinician support — abrupt discontinuation of chronic benzodiazepines is medically dangerous (seizure risk). Standard taper schedules are too fast for many patients.
- •For patients with severe anxiety disorders trapped on chronic benzodiazepines, ketamine's rapid antidepressant/anxiolytic effect can stabilize anxiety enough to enable a slow benzodiazepine taper.
Medications most associated with this
What this is
Benzodiazepine rebound anxiety is anxiety that appears or intensifies because of the medication itself, not the underlying condition. Three patterns: (1) Interdose rebound — anxiety appears in the hours before the next dose, often worse than baseline. (2) Tolerance — over weeks-to-months on a stable dose, anxiety levels gradually creep back up despite the medication still being "on board." (3) Withdrawal rebound — anxiety spikes during tapering or after stopping, often peaking in the first 1-2 weeks. Patients typically describe the rebound anxiety as feeling like the original anxiety but "amplified" or "louder," sometimes with new physical symptoms (tremor, sweating, agitation) that weren't part of the original presentation.
Why it happens
Benzodiazepines enhance GABA's inhibitory effect at the GABA-A receptor. With chronic exposure, the brain downregulates GABA receptors and adjusts downstream signaling to compensate. The result: when benzodiazepine levels fall (between doses or during tapering), the brain experiences a relative deficit in inhibitory signaling, which clinically presents as anxiety. The medication that initially produced anxiolysis eventually produces rebound anxiety as a feature of its long-term pharmacology. Recent reviews confirm the mechanism and recommend earlier deprescribing to avoid the rebound-tolerance loop.
Typical timeline
Interdose rebound: appears within hours of a dose wearing off, particularly with short-half-life agents (Xanax can produce rebound within 4-6 hours; Ativan within 6-8). Tolerance: develops over weeks-to-months on a stable dose. Withdrawal rebound: appears within 24-72 hours of dose reduction, peaks in days 5-14, can persist for weeks-to-months depending on duration of use and taper rate. Some patients experience prolonged withdrawal lasting 6-18 months.
Management options
Discuss with your prescriber before adjusting any medication. These are options to bring up in conversation.
Recognize the pattern (essential first step)
Many patients interpret rebound anxiety as their underlying anxiety worsening and request dose increases — perpetuating the cycle. Identifying the iatrogenic component is the prerequisite for breaking out. A psychiatrist familiar with benzodiazepine tolerance can help distinguish.
Switch from short-acting to long-acting agent
Cross-tapering from alprazolam or lorazepam to diazepam (longer half-life) reduces interdose rebound and provides a more stable platform for subsequent tapering. The Ashton manual is the most-cited protocol for this approach.
Slow taper (months, not weeks)
Standard benzodiazepine tapers are too fast for patients who've been on the medication for years. Tapering over 6-18 months with small dose reductions (5-10% every 2-4 weeks) is increasingly recommended. The Maudsley Deprescribing Guidelines and Ashton manual both provide schedules.
Add an SSRI or buspirone for sustained anxiolysis
For patients with underlying anxiety disorder, starting an SSRI or buspirone several weeks before beginning the benzodiazepine taper provides an alternative anxiety treatment that's in place during the taper. Reduces the risk of relapse and supports the taper.
CBT or ACT therapy alongside the taper
Therapy provides skills for managing breakthrough anxiety during the taper without escalating the benzodiazepine. Particularly useful for patients whose original anxiety has been masked by the medication for years.
Mechanism switch to ketamine
For patients with severe anxiety trapped on chronic benzodiazepines, ketamine's rapid antidepressant/anxiolytic effect can stabilize symptoms enough to enable the slow benzodiazepine taper. The mechanism (NMDA/glutamate) is non-overlapping, so it doesn't add to the GABA-related tolerance issue.
Where ketamine fits
Patients on chronic benzodiazepines for severe anxiety often face a difficult choice: stay on the medication and accept the rebound-tolerance pattern, or attempt a slow taper that exposes them to months of withdrawal. Ketamine offers a third option: rapid anxiolytic effect via a non-GABA mechanism. With ketamine in place, the benzodiazepine taper can proceed at the slow pace needed without leaving the patient in unmanaged anxiety. The mechanisms don't overlap (GABA vs NMDA/glutamate), so ketamine doesn't add to the tolerance issue benzodiazepines created.
Check eligibility for ketamine therapy5-minute screening · Reviewed by a board-certified physician · FL & NJ
Frequently asked
How do I know if my anxiety is rebound from the medication or my original anxiety?
Two tells. First, timing: rebound anxiety typically appears in the hours before your next dose, peaks just before the dose, and improves shortly after taking it. Original anxiety has more situational and emotional triggers. Second, character: rebound anxiety often feels like baseline anxiety "amplified" or accompanied by physical symptoms (tremor, sweating, agitation) that weren't part of the original presentation.
Is it safe to stop benzodiazepines cold turkey?
No — for chronic users, abrupt discontinuation is medically dangerous and can produce seizures. Always taper benzodiazepines with clinician support. The exception is very short-term use (days to a week or two), where the brain hasn't fully adapted and abrupt cessation may be tolerable. For anyone on benzodiazepines for months or longer, taper.
How long should I taper benzodiazepines?
Depends on duration of use, dose, and the agent. For patients on chronic benzodiazepines (1+ years), tapering over 6-18 months with small dose reductions is increasingly recommended. The Ashton manual and Maudsley Deprescribing Guidelines provide specific schedules. A psychiatrist or pharmacist experienced with benzodiazepine deprescribing is the right resource.
Will ketamine help with anxiety while I taper benzos?
For many patients, yes — ketamine's rapid anxiolytic effect can stabilize anxiety through the taper. The mechanisms don't overlap (NMDA/glutamate vs GABA), so ketamine doesn't add to the benzodiazepine tolerance issue. Many patients are able to complete benzodiazepine tapers on ketamine maintenance that they couldn't complete on tapering alone.
My doctor keeps increasing my Xanax dose — is that the right approach?
Often not. If you're needing dose increases over time, that's a sign of tolerance, not necessarily that the original anxiety is worsening. The right response is usually to address the tolerance through tapering and alternative anxiolytic strategies, not to chase escalating doses. Consider a second opinion if your prescriber is repeatedly increasing the dose without discussing alternatives.
Don’t stop your medication on your own
Even mild side effects deserve a clinical conversation. Stopping or adjusting antidepressants without coordination with your prescriber can cause discontinuation syndrome, depression breakthrough, or both. Bring these options to your next appointment.
References
- Figg JW et al. 2026, Annals of General Psychiatry. Benzodiazepines at the crossroads — review of therapeutic value vs tolerance, dependence, and withdrawal complications. PMID 41622184
- Shuey B et al. 2026, JAMA Intern Med. Implementing benzodiazepine deprescribing in primary care — review of tapering strategies and patient outcomes. PMID 41247740
- Navarrete F et al. 2026, Int J Mol Sci. Benzodiazepine dependence: clinical and molecular aspects — mechanism of tolerance, rebound, and withdrawal at the GABA-A receptor level. PMID 41683852
- Sanacora G et al. 2017, JAMA Psychiatry. APA consensus on ketamine in mood disorders — addresses use cases including severe comorbid anxiety where chronic benzodiazepine exposure is problematic. PMID 28249076